Stem Cell Factor Therapy for Ischemic Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell therapies for ischemic tissue injury face challenges such as inefficient delivery methods, complex regulatory networks, and potential arrhythmia risks from injecting non-cardiac cells into the heart, limiting their effectiveness in treating conditions like myocardial infarction and cardiovascular diseases.
Innovation Solution
The method involves delivering a nucleic acid encoding Stem Cell Factor (SCF) to the site of injury, which mobilizes c-kit expressing stem cells and mast cells to promote tissue repair, using vectors like adenoviral or retroviral vectors, and potentially combining with stem cell administration to enhance cardiovascular tissue repair.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct injection of stem cells is used to treat ischemic tissue injury, then tissue repair is promoted, but arrhythmia risk increases and delivery efficiency decreases
Solution Approach 1:
The patent extracts the therapeutic function of stem cells (tissue repair and neovascularization) and separates it from the actual cell injection. Instead of injecting whole stem cells, the invention uses SCF protein or SCF-encoding nucleic acids to stimulate endogenous c-kit+ stem cells to proliferate and differentiate, thereby achieving tissue repair without introducing foreign cells that could cause arrhythmia.
Solution Approach 2:
The patent introduces SCF (Stem Cell Factor) as an intermediary substance that mediates between the treatment goal and the body's natural repair mechanisms. SCF acts as a signaling molecule that activates endogenous c-kit+ stem cells, serving as a safe intermediary that avoids the direct risks of cell injection while still triggering the desired regenerative response.
2Reliability
If ex-vivo processing of stem cells is performed to enhance therapeutic effect, then tissue repair capability is improved, but manufacturing complexity and regulatory burden increase
Solution Approach 1:
The patent enables the patient's own body to perform the therapeutic function without external intervention in cell processing. By administering SCF or SCF-encoding nucleic acids, the body's endogenous c-kit+ stem cells are activated to self-replicate and self-differentiate into needed cell types, eliminating the need for complex ex-vivo cell processing, expansion, and quality control procedures.
Solution Approach 2:
The patent performs preliminary action by administering SCF or SCF-encoding nucleic acids before the actual tissue repair is needed. This pre-activation of the stem cell system allows the body to be primed for repair, avoiding the need for complex last-minute cell processing and preparation that would increase manufacturing complexity.
3Reliability
If non-cardiac stem cells are injected into the heart to promote repair, then tissue regeneration is enhanced, but arrhythmia risk increases
Solution Approach 1:
The patent extracts the beneficial regenerative effect from the concept of injecting foreign stem cells and replaces it with activation of endogenous cardiac-resident c-kit+ stem cells. This extraction eliminates the risk of arrhythmia associated with non-cardiac cell injection while preserving the tissue regeneration benefit through paracrine signaling and differentiation of native cells.
Solution Approach 2:
The patent applies local quality by targeting the activation of stem cells specifically within the cardiac tissue using locally-administered SCF or SCF-encoding nucleic acids. This localized approach ensures that only cardiac-resident c-kit+ cells are activated, maintaining the local cellular environment and avoiding the introduction of foreign cell types that could disrupt electrical conduction.
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to the use of stem cell factor (SCF) for the treatment of ischemic injured tissue such as in cardiovascular disease. The method involves administration of a nucleic acid encoding SCF, wherein the nucleic acid is delivered to the site of the injury and is incorporated into cells which then express the SCF.